Compare AGIO & QDEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AGIO | QDEL |
|---|---|---|
| Founded | 2007 | 1979 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2013 | N/A |
| Metric | AGIO | QDEL |
|---|---|---|
| Price | $28.65 | $28.26 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 6 |
| Target Price | $36.25 | ★ $40.00 |
| AVG Volume (30 Days) | ★ 1.3M | 921.4K |
| Earning Date | 02-12-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $44,791,000.00 | ★ $2,714,400,000.00 |
| Revenue This Year | $27.83 | N/A |
| Revenue Next Year | $134.79 | $2.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 36.26 | N/A |
| 52 Week Low | $22.24 | $19.50 |
| 52 Week High | $46.00 | $46.24 |
| Indicator | AGIO | QDEL |
|---|---|---|
| Relative Strength Index (RSI) | 52.75 | 41.25 |
| Support Level | $26.25 | $27.19 |
| Resistance Level | $28.87 | $35.58 |
| Average True Range (ATR) | 1.09 | 2.18 |
| MACD | 0.25 | -0.59 |
| Stochastic Oscillator | 74.29 | 13.42 |
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
QuidelOrtho Corp is engaged in the development, manufacturing and marketing of rapid diagnostic testing solutions. The company is engaged in immunoassay and molecular testing, clinical chemistry and transfusion medicine which helps clinicians and patients to make decisions across the globe. Geographically the company has its presence in North America, EMEA, China and Other countries. It generates majority if its revenue from North America.